Track 12: Value and Access
The healthcare landscape is evolving into one assessed on value, and there is a need to understand the impact of this movement on all stakeholders: providers, payers, biopharma, and patients. Value and access to medicines are complex issues that require analysis from health economic and philosophical perspectives. The Value and Access track will bring together global regulators, industry leaders, academics, patients, and payers who will facilitate discussions and address questions such as:
- What information and evidence are being used to define value?
- What are the ethical considerations when determining access to medical products?
- Do strategies that increase diversity and inclusion in clinical trial research improve access to medicines? Who is making or influencing access decisions?
- How can real-world data be leveraged to drive access to medicines?
- What are the regulatory and legal considerations
DIA recommends this track and associated sessions to payers, bioethicists, health economics outcomes researchers, health economists, statisticians, data modelers, clinical researchers, post-marketing professionals, and regulatory affairs professionals.
Included Topic Areas
Comparative effectiveness research, diversity, equity, and inclusion, ethical considerations in clinical research, health technology assessment, real-world outcomes, value-based healthcare; drug pricing, reimbursement and access, commercialization, product lifecycle considerations.
Priority Topics
- Inflation Reduction Act (IRA) 9 Months After the First Round of Implementation
- What is the Value/Role of ICER in the US and Today and in the Future?
- Let’s Talk about the Evolution of Health Care Toward Value-Based Care
- How do Drug Shortages Affect Patients’ Access to Medicines?
- The Centers for Medicare and Medicaid Services (CMS) Payment for Alzheimer’s Drugs and the Registry Requirements That tie into Coverage
- Prescription to Over-the-Counter (OTC) Switches with the Potential for Huge Impact